2007-06-15

Inovelon(R) A New Treatment for Lennox-Gastaut Syndrome Launched in Europe


London (ots/PRNewswire) -

- First Treatment Licensed Specifically for LGS Offers New Hopefor Patients With Epilepsy

Eisai Europe Limited, (Headquarters: London, President YutakaTsuchiya) today announced the launch in Germany and Scandinavia ofits new anti-epileptic agent Inovelon (rufinamide) indicated foradjunctive therapy in Lennox-Gastaut Syndrome (LGS).

Inovelon, a structurally novel compound, is the first treatmentlicensed by the European Medicines Agency (EMEA) specifically forLGS, a severe form of generalised epilepsy that develops in earlychildhood.

Symptoms of LGS include a variety of seizure types, withtonic-atonic seizures being the most common. Atonic seizures (rapidloss of muscle tone and consciousness), and tonic seizures (wheremuscles contract continuously typically producing a stiffening of thelegs and arms) lead to the sudden falls seen in LGS patients known as'drop attacks'. Absence seizures (staring spells) and myoclonicseizures (sudden muscle jerks) are also commonly observed. Allchildren with LGS will experience varying degrees of developmentaldelay and behavioral problems.

In a placebo-controlled study Inovelon was found to produce amedian reduction in seizure frequency of 42.5% (p=<0.0001) for dropattacks, and reduce the occurrence of total seizures by 32.7%(p=<0.0015). These differences between Inovelon and placebo wereobserved as early as week two during the study, suggesting a fastonset of action. Results from the extension study suggested that forsubjects continuing on Inovelon, seizure reduction appeared to bemaintained in the long term (up to two years).

Approximately 11,000 people across Western Europe are currentlydiagnosed with LGS, and it is hoped that the launch of Inovelon willcontribute to improved patient and carer quality of life.

Notes to Editors

About Eisai Europe Ltd.

Established in 1989, Eisai Europe Ltd. is the Europeanpharmaceutical subsidiary of Eisai Co. Ltd., a research-based humanhealth care (hhc) company that discovers, develops and marketsproducts throughout the world. Through a global network of researchfacilities, manufacturing sites and marketing subsidiaries, Eisaiactively participates in all aspects of the worldwide health caresystem. Eisai focuses its efforts in two therapeutic areas;integrative neurology and integrative oncology/critical care. Eisaiemploys more than 9,000 people worldwide.

About Inovelon(R)

Inovelon is a structurally novel compound that acts as abroad-spectrum anticonvulsant originally discovered and developed byNovartis Pharma AG. Eisai signed an in-licensing agreement for thecompound with Novartis in February 2004.

Availability

Commercial availability of Inovelon across Europe is dependantupon local regulatory requirements and pricing and reimbursementnegotiations. Inovelon is currently available in the followingmarkets;

- Austria - Denmark - Finland - Germany - Iceland - Norway - Sweden

and will be launched in other European countries in due course.

ots Originaltext: Eisai Europe Ltd.Im Internet recherchierbar: http://www.presseportal.de

Contact:For further information contact:, Andrew Day, Communications Director, Eisai Europe Ltd, +44-(0)208-600-1400

Eisai Europe Ltd.

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs

News

Inovelon(R) A New Treatment for Lennox-Gastaut Syndrome Launched in Europe

Medizin-News